Compare FTAI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTAI | RPRX |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | 985 | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 22.0B |
| IPO Year | N/A | 2020 |
| Metric | FTAI | RPRX |
|---|---|---|
| Price | $250.17 | $55.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $274.67 | $51.40 |
| AVG Volume (30 Days) | 1.0M | ★ 3.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | 0.75% | ★ 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $32.73 | $38.63 |
| Revenue Next Year | $51.41 | $4.73 |
| P/E Ratio | ★ $65.85 | $82.04 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $109.90 | $33.37 |
| 52 Week High | $323.51 | $55.86 |
| Indicator | FTAI | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 65.22 |
| Support Level | $216.34 | $35.35 |
| Resistance Level | $261.25 | N/A |
| Average True Range (ATR) | 13.61 | 1.16 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 75.24 | 78.31 |
FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.